睿知中国医院研究地图
候选清单

嘉兴

Affiliated Hospital of Jiaxing University

在本站收录的 61 种疾病中,这家医院列在其中 2 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

Affiliated Hospital of Jiaxing University的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肺癌Lung cancer32 篇牵头论文
  2. 胰腺癌Pancreatic cancer9 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、乳腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 0.1%。

牵头论文
32
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 8820222023: 5520232024: 5520242025: 772025

嘉兴有 1 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery
    分期
    不分期
    开始
    2026-10
    发布
    登记号
    NCT07849400

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心嘉兴、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科

这些论文过半是实验室或动物研究。

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文32
  1. Circ_0105487 Promotes the Metastasis of Triple-Negative Breast Cancer via Epithelial-Mesenchymal Transition.2026Biotechnology and applied biochemistry
  2. Progress in Development of Lung Cancer Survival Prediction Models Using Machine Learning Based on SEER Database.2025Cancer investigation
  3. Longitudinal single-cell RNA model aids prediction of EGFR-TKI resistance.2025Carcinogenesis
  4. ERCC6L-mediated stabilization of HIF-1α enhances glycolysis and stemness properties of lung adenocarcinoma cells.2025Cell death & disease免费全文
  5. TCF3 activates VEGFA transcription and reinforces PD-L1 expression in lung adenocarcinoma cells via NF-κB to attenuate the cytotoxicity of CD8+ T cells.2025Expert review of clinical immunology
  6. Akkermansia muciniphila-derived outer membrane protein Amuc_1100 promotes acetylation of RING Finger Protein 181 promoter and mediates Autophagy Related 7 ubiquitination to activate CD8+ T cells in lung adenocarcinoma.2025International journal of biological macromolecules
  7. Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation.2025Journal of translational medicine免费全文
  8. Network pharmacological mechanism and molecular experimental validation of artemisinin in the treatment of lung adenocarcinoma.2025Toxicology and applied pharmacology
  9. MiR-301b-3p can be used as a Potential Marker for the Diagnosis of Lung Adenocarcinoma.2024Combinatorial chemistry & high throughput screening
  10. LncRNA HCG11 enhances the chemosensitivity of non-small cell lung cancer cells to Gemcitabine via miR-17-5p/p21 axis.2024Expert review of anticancer therapy
  11. CT-based intratumoral and peritumoral deep transfer learning features prediction of lymph node metastasis in non-small cell lung cancer.2024Journal of X-ray science and technology
  12. Liquid Biopsy in Lung Cancer: Nano-Flow Cytometry Detection of Non-Small Cell Lung Cancer in Blood.2024Laboratory investigation; a journal of technical methods and pathology
  13. Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma and through JAK-STAT signalling pathway.2024Microbial biotechnology免费全文
  14. EIF4A3-induced circular RNA SCAP facilitates tumorigenesis and progression of non-small-cell lung cancer via miR-7/SMAD2 signaling.2023Environmental science and pollution research international免费全文
  15. Preparation, characterisation, and in vitro cancer-suppression function of RNA nanoparticles carrying miR-301b-3p Inhibitor.2023IET nanobiotechnology免费全文
  16. Investigation of the Potential Correlation Between RNA-Binding Proteins in the Evolutionarily Conserved MEX3 Family and Non-small-Cell Lung Cancer.2023Molecular biotechnology免费全文
  17. TFAP2A activates HMGA1 to promote glycolysis and lung adenocarcinoma progression.2023Pathology, research and practice
  18. Sublobar resection versus lobectomy in the treatment of synchronous multiple primary lung cancer.2023World journal of surgical oncology免费全文
  19. Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort.2022BMC cancer免费全文
  20. A Clinical Study on Microwave Ablation in Combination with Chemotherapy in Treating Peripheral IIIB-IV Non-Small Cell Lung Cancer.2022Cancer biotherapy & radiopharmaceuticalsRCT
  21. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.2022Cellular signalling
  22. TRIM66 Promotes Malignant Progression of Non-Small-Cell Lung Cancer Cells via Targeting MMP9.2022Computational and mathematical methods in medicine免费全文
  23. TRIM66 hastens the malignant progression of non-small cell lung cancer via modulating MMP9-mediated TGF-β/SMAD pathway.2022Cytokine
  24. Prognostic value of metabolic genes in lung adenocarcinoma via integrative analyses.2022Genomics
  25. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.2022Medical oncology (Northwood, London, England)
  26. The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer.2022The Journal of international medical research免费全文
  27. MiR-133b suppresses the proliferation, migration and invasion of lung adenocarcinoma cells by targeting SKA3.2021Cancer biology & therapy免费全文
  28. Value of Growth/Differentiation Factor 15 in Diagnosis and the Evaluation of Chemotherapeutic Response in Lung Cancer.2021Clinical therapeutics
  29. DLC1 inhibits lung adenocarcinoma cell proliferation, migration and invasion via regulating MAPK signaling pathway.2021Experimental lung research
  30. New biomarker for lung cancer - focus on circSETD3.2021Journal of biological regulators and homeostatic agents
  31. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.2021Journal of cancer research and clinical oncology免费全文
  32. MIR-301b-3p Promotes Lung Adenocarcinoma Cell Proliferation, Migration and Invasion by Targeting DLC1.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery即将招募NCT07849400研究中心不分期2026-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.2%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 3320242025: 222025

嘉兴有 2 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胰腺癌开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文9
  1. Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study.2026Journal of proteome research
  2. Single-cell and multi-omics analysis identifies TRIM9 as a key ubiquitination regulator in pancreatic cancer.2025Frontiers in immunology免费全文
  3. Impact of microvasculature invasion subtype (MVI vs. LVI) and associated risk factors on survival outcomes in pancreatic cancer after curative surgery.2025World journal of surgical oncology免费全文
  4. Nomogram incorporating prognostic immune-inflammatory-nutritional score for survival prediction in pancreatic cancer: a retrospective study.2024BMC cancer免费全文
  5. Construction of a combined prognostic model for pancreatic ductal adenocarcinoma based on deep learning and digital pathology images.2024BMC gastroenterology免费全文
  6. miR-630 as a therapeutic target in pancreatic cancer stem cells: modulation of the PRKCI-Hedgehog signaling axis.2024Biology direct免费全文
  7. A necroptosis related prognostic model of pancreatic cancer based on single cell sequencing analysis and transcriptome analysis.2022Frontiers in immunology免费全文
  8. Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study.2021Canadian journal of gastroenterology & hepatology免费全文
  9. LINC00261 elevation inhibits angiogenesis and cell cycle progression of pancreatic cancer cells by upregulating SCP2 via targeting FOXP3.2021Journal of cellular and molecular medicine免费全文

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

Affiliated Hospital of Jiaxing University

嘉兴

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

没有匹配到医院级的 ROR 记录。

提出更正下载数据